12:00 AM
 | 
Aug 22, 2016
 |  BioCentury  |  Finance

Tioma's broad basket

Tioma hopes to show clinical POC for multiple anti-CD47 mAbs with $86M A round

Tioma Therapeutics Inc. will avoid putting its eggs in one basket and use last week's tranched $86 million series A round to launch a broad clinical program targeting CD47.

President and CEO John Donovan said the round should enable Tioma to generate clinical proof of concept over the next three years for multiple anti-CD47 antibodies across a range of undisclosed tumor types, both as monotherapies and in combination with checkpoint inhibitors.

RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and SR One co-led the round.

RiverVest's John McKearn, who will serve as Tioma's chairman, said the biotech's...

Read the full 502 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >